about
Eosinophilic bioactivities in severe asthmaClinical characteristics of adults with chronic rhinosinusitis and specific antibody deficiency.Dead or alive: Deoxyribonuclease I sensitive bacteria and implications for the sinus microbiome.Albuterol Overuse: A Marker of Psychological Distress?Chapter 12: Asthma: principles of treatment.Chapter 21: Urticaria and angioedema.Update in Asthma 2014.Alteration in Bacterial Culture After Treatment With Topical Mupirocin for Recalcitrant Chronic Rhinosinusitis.Chronic Infection and Severe Asthma.Association of aeroallergen sensitization and atopic disease in the Sonoran Desert.Pathophysiology of Immediate Reactions to Injectable Gadolinium-based Contrast Agents.Small airways disease and severe asthma.A Distinct Low Lung Function Trajectory from Childhood to the Fourth Decade of Life.Eosinophilic and Non-Eosinophilic Asthma.Editorial: Innovative steps toward understanding sinonasal disease, improving diagnostics and optimizing patient care.Iatrogenic autoimmune progesterone dermatitis treated with a novel intramuscular progesterone desensitization protocol.Prevalence of Asthma in School Children on the Arizona-Sonora Border.Management of Severe Asthma before Referral to the Severe Asthma Specialist.Complications of sinusitisAspergillosis, eosinophilic esophagitis, and allergic rhinitis in signal transducer and activator of transcription 3 haploinsufficiencyUse of biomarkers to identify phenotypes and endotypes of severeasthmaNon-atopic rhinitis at age 6 is associated with subsequent development of asthmaPredictors of inhaled corticosteroid taper failure in adults with asthma
P50
Q26744175-3A6D0E8A-9BB9-4E05-8579-F9DFC67790ECQ35347947-0948B956-8C1A-40FC-ACCA-0090DA099702Q35881156-C3358D88-818B-4556-8DA6-2D16047AF8C8Q36271433-CAE0C5D1-4A60-49C8-BCED-7CAF6F76CDA5Q38026182-13F10FFC-4D96-4180-945F-A8A891DD2FC1Q38026189-99101152-D9DA-4517-B52A-8B27F096DC6FQ38547604-596F5D75-B56E-48BB-B204-4AC7654CA8D7Q38683970-44634E5D-96F0-48BA-85C3-A76343DD6359Q38892958-B9758641-975E-4983-98A6-73401592D7CBQ38924892-29B7942F-3084-4764-A4DC-7FAF2A923460Q38982565-8E5F2874-D8FF-4F1F-85DE-21A53F1CC4D3Q39397730-ECAFC855-6E78-44C3-8975-60C71F871836Q39431780-7278942C-4D56-4C86-A092-1E9D73D324F6Q40046428-15B1BE48-C60E-4BF5-93C9-80986E85FFADQ42693898-CF50D36C-7322-4424-879D-8CC8DC03AC46Q46206749-542FBB8E-649C-49CF-9467-DD6C0A00F92FQ47709189-CB04140C-46D9-418D-AD13-DCC1E3DD628FQ52583301-15E6BA4D-33DF-4EC6-918D-BDAB73B14CECQ87998188-ED11150C-9AF3-400A-B361-5F8E9C16EBCCQ88872572-31296F51-3430-4B68-AA4F-128E3323AA12Q90613708-887A43EB-A221-46F7-97A4-7DA0DC065F43Q91469370-824BEEFD-04CF-4ACC-9522-E92FACC04EF6Q91627660-D7DFE575-2C88-4ABD-B795-2A4D9D601201
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Tara F Carr
@ast
Tara F Carr
@de
Tara F Carr
@en
Tara F Carr
@es
Tara F Carr
@fr
Tara F Carr
@it
Tara F Carr
@nl
type
label
Tara F Carr
@ast
Tara F Carr
@de
Tara F Carr
@en
Tara F Carr
@es
Tara F Carr
@fr
Tara F Carr
@it
Tara F Carr
@nl
prefLabel
Tara F Carr
@ast
Tara F Carr
@de
Tara F Carr
@en
Tara F Carr
@es
Tara F Carr
@fr
Tara F Carr
@it
Tara F Carr
@nl
P106
P1153
55802437700
P31
P496
0000-0002-6397-5396